Accelerated TMS for MDD

NCT07147218 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-11-21

No results posted yet for this study

Summary

An open-label, multi-center, prospective study to evaluate feasibility and efficacy of accelerated TMS for patients with Major Depressive Disorder (MDD).

Conditions

Interventions

DEVICE

TMS

transcranial magnetic stimulation - DASH 36 treatment delivered in 5 days

Sponsors & Collaborators

  • Neuronetics

    lead OTHER

Principal Investigators

  • Eleanor Cole, PhD · Neuronetics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-21
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07147218 on ClinicalTrials.gov